

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Zanubrutinib for treating chronic lymphocytic
leukaemia [ID5078]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

At the scoping stage, the company noted that chronic lymphocytic leukaemia is common in older adults. The committee considered issues relating to disease prevalence cannot usually be addressed by technology appraisals. But the committee considered whether its recommendations make access to treatment more difficult for groups with protected characteristics such as age.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

The company's submission did not include people without a 17p deletion or TP53 mutation for whom FCR or BR is suitable. Patient submissions highlighted that this would potentially deny younger and fitter people access to a new treatment option that is well tolerated. The committee acknowledged this a potential equality issue. However, it considered this could not be resolved in the absence of evidence in this population. The committee concluded that evidence from SEQUOIA trial was applicable to everyone with untreated CLL. It suggested that the company could present analysis for the whole untreated CLL population.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No
4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No
5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No
6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A
7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Yes, sections 3.5 and 3.17 of draft guidance.

Approved by Associate Director (name): Ross Dent

Date: 24/07/2023

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of zanubrutinib for treating chronic lymphocytic leukaemia [ID5078]

2 of 4

Issue date: October 2023

Final draft guidance

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No.

The company presented analysis for the subgroup for whom FCR and BR is suitable in response to consultation. However, the cost-effectiveness estimate compared with ibrutinib plus venetoclax was substantially higher than what is usually considered an effective use of NHS resources. So zanubrutinib could not be recommended in this population.

1. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

2. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

4. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, sections 3.5 and 3.18 of draft guidance.

Approved by Associate Director (name): Ross Dent

Date: 02/10/2023